{"DataElement":{"publicId":"3135398","version":"1","preferredName":"Person Concomitant Prostate Carcinoma Pathologic T Stage","preferredDefinition":"Code to represent the extent of incidental or concomitant prostate carcinoma in the primary tumor site based on pathological assessment and the staging guidelines from the AJCC edition 7.0.","longName":"3135386v1.0:3135389v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3135386","version":"1","preferredName":"Person Concomitant Prostate Carcinoma Occurrence","preferredDefinition":"Person; a human being._Concomitant; following as a consequence._Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Occurrence; an instance of something happening.","longName":"3135384v1.0:2234856v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3135384","version":"1","preferredName":"Person Concomitant Prostate Carcinoma","preferredDefinition":"Person; a human being.:Concomitant; following as a consequence.:Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C25190:C25730:C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC21DA4-F064-1071-E040-BB89AD43102A","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234856","version":"1","preferredName":"Occurrence","preferredDefinition":"Occurrence; an instance of something happening.","longName":"C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-72B8-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC21DA4-F072-1071-E040-BB89AD43102A","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3135389","version":"1","preferredName":"Prostate Carcinoma Pathologic T Stage","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Pathologic; caused by or altered by or manifesting disease or pathology._One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3135389v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"pT4","valueDescription":"Invasion of rectum, levator muscles and/or pelvic wall","ValueMeaning":{"publicId":"3135390","version":"1","preferredName":"Invasion of rectum, levator muscles and/or pelvic wall","longName":"3135390","preferredDefinition":"Prostate cancer with tumor invading the rectum, levator muscles, and/or pelvic wall. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT4 TNM Finding v7","conceptCode":"C89203","definition":"Prostate cancer with tumor invading the rectum, levator muscles, and/or pelvic wall. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-6569-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-6582-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT3b","valueDescription":"Seminal vesicle invasion","ValueMeaning":{"publicId":"3135391","version":"1","preferredName":"Seminal vesicle invasion","longName":"3135391","preferredDefinition":"Prostate cancer with seminal vesicle invasion. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT3b TNM Finding v6 and v7","conceptCode":"C48242","definition":"Prostate cancer with seminal vesicle invasion. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-658C-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-65A5-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT3a","valueDescription":"Extraprostatic extension or microscopic invasion of bladder neck","ValueMeaning":{"publicId":"3135392","version":"1","preferredName":"Extraprostatic extension or microscopic invasion of bladder neck","longName":"3135392","preferredDefinition":"Prostate cancer with extraprostatic extension or microscopic invasion of bladder neck.  Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease). (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT3a TNM Finding v7","conceptCode":"C89202","definition":"Prostate cancer with extraprostatic extension or microscopic invasion of bladder neck.  Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease). (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-65AF-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation for added UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-65C8-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT3","valueDescription":"Extraprostatic extension of tumor","ValueMeaning":{"publicId":"3135393","version":"1","preferredName":"Extraprostatic extension of tumor","longName":"3135393","preferredDefinition":"Prostate cancer with extraprostatic extension. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT3 TNM Finding v6 and v7","conceptCode":"C48240","definition":"Prostate cancer with extraprostatic extension. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-65D2-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-65EB-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT2c","valueDescription":"Tumor involves both lobes, bilateral disease","ValueMeaning":{"publicId":"3135394","version":"1","preferredName":"Tumor involves both lobes, bilateral disease","longName":"3135394","preferredDefinition":"Prostate cancer involving both lobes of the prostate gland. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT2c TNM Finding v6 and v7","conceptCode":"C48239","definition":"Prostate cancer involving both lobes of the prostate gland. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-65F5-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-660E-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT2b","valueDescription":"Tumor unilateral, involving more than one-half of side but not both sides","ValueMeaning":{"publicId":"3135395","version":"1","preferredName":"Tumor unilateral, involving more than one-half of side but not both sides","longName":"3135395","preferredDefinition":"Prostate cancer involving more than one-half of one lobe, but not both lobes of the prostate gland. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT2b TNM Finding v6 and v7","conceptCode":"C48238","definition":"Prostate cancer involving more than one-half of one lobe, but not both lobes of the prostate gland. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-6618-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-6631-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT2a","valueDescription":"Tumor unilateral, one-half of one side or less","ValueMeaning":{"publicId":"3135396","version":"1","preferredName":"Tumor unilateral, one-half of one side or less","longName":"3135396","preferredDefinition":"Prostate cancer limited to one-half or less of one lobe of the prostate gland. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT2a TNM Finding v6 and v7","conceptCode":"C48237","definition":"Prostate cancer limited to one-half or less of one lobe of the prostate gland. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-663B-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-6654-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT2","valueDescription":"Tumor confined with prostate","ValueMeaning":{"publicId":"3135397","version":"1","preferredName":"Tumor confined with prostate","longName":"3135397","preferredDefinition":"Prostate cancer confined to the prostate gland. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT2 TNM Finding v6 and v7","conceptCode":"C48236","definition":"Prostate cancer confined to the prostate gland. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-665E-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-6677-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT0","valueDescription":"No evidence of primary tumor","ValueMeaning":{"publicId":"2981337","version":"1","preferredName":"No evidence of primary tumor","longName":"2981337","preferredDefinition":"No morphologic evidence of primary tumor, in accordance with TNM classification system guidelines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pT0 TNM Finding","conceptCode":"C48758","definition":"No morphologic evidence of primary tumor, in accordance with TNM classification system guidelines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C86ABC7-C701-678D-E040-BB89AD432C56","latestVersionIndicator":"Yes","beginDate":"2010-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-01-06","modifiedBy":"LUY","dateModified":"2015-01-29","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-6681-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pTX","valueDescription":"Primary tumor cannot be assessed","ValueMeaning":{"publicId":"3040286","version":"1","preferredName":"Primary tumor cannot be assessed","longName":"3040286","preferredDefinition":"A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TX TNM Finding","conceptCode":"C48737","definition":"A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83221F6F-55E7-6011-E040-BB89AD431C5D","latestVersionIndicator":"Yes","beginDate":"2010-03-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8FC04DC3-668B-CF3E-E040-BB89AD43512D","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","deletedIndicator":"No"},{"value":"pT1c","valueDescription":"Tumor was found in a needle biopsy performed due to an elevated serum PSA","ValueMeaning":{"publicId":"3442953","version":"1","preferredName":"Tumor was found in a needle biopsy performed due to an elevated serum PSA","longName":"3442953","preferredDefinition":"A pathologic primary tumor TNM stage finding.  The definition of pT1c stage finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1c stage finding is defined as follows: cancer with tumor size more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for fallopian tube cancer, pT1c stage finding is defined as follows: cancer with tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pT1c TNM Finding","conceptCode":"C48763","definition":"A pathologic primary tumor TNM finding. The definition of pT1c  finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1c finding is defined as follows: cancer with tumor size more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for fallopian tube cancer, pT1c finding is defined as follows: cancer with tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE8A053C-B48D-0643-E040-BB89AD436B32","latestVersionIndicator":"Yes","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE8A053C-B4A6-0643-E040-BB89AD436B32","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"ONEDATA","dateModified":"2012-04-25","deletedIndicator":"No"},{"value":"pT1b","valueDescription":"Tumor was incidentally found in greater than 5% of prostate tissue resected","ValueMeaning":{"publicId":"3442954","version":"1","preferredName":"pT1b Stage Finding","longName":"3442954","preferredDefinition":"A pathologic primary tumor TNM stage finding.  The definition of pT1b stage finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1b stage finding is defined as follows: cancer with tumor size more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for lung cancer, pT1b stage finding is defined as follows: cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pT1b TNM Finding","conceptCode":"C48761","definition":"A pathologic primary tumor TNM finding. The definition of pT1b finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1b finding is defined as follows: cancer with tumor size more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for lung cancer, pT1b finding is defined as follows: cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE8A053C-B4B0-0643-E040-BB89AD436B32","latestVersionIndicator":"Yes","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"COLBERTM","dateModified":"2022-08-22","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":"8/22/22 Updated LN to pT1b Stage Finding. MR;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE8A053C-B4C9-0643-E040-BB89AD436B32","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"ONEDATA","dateModified":"2012-04-25","deletedIndicator":"No"},{"value":"pT1a","valueDescription":"Tumor was incidentally found in less than 5% of prostate tissue resected (for other reasons)","ValueMeaning":{"publicId":"3442955","version":"1","preferredName":"Tumor was incidentally found in less than 5% of prostate tissue resected (for other reasons)","longName":"3442955","preferredDefinition":"A pathologic primary tumor TNM stage finding.  The definition of pT1a stage finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1a stage finding is defined as follows: cancer with tumor size more than 0.1 cm, but not more than 0.5 cm in greatest dimension; for lung cancer, pT1a stage finding is defined as follows: cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pT1a TNM Finding","conceptCode":"C48760","definition":"A pathologic primary tumor TNM finding.  The definition of pT1a finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1a finding is defined as follows: cancer with tumor size more than 0.1 cm, but not more than 0.5 cm in greatest dimension; for lung cancer, pT1a finding is defined as follows: cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE8A053C-B4D3-0643-E040-BB89AD436B32","latestVersionIndicator":"Yes","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE8A053C-B4EC-0643-E040-BB89AD436B32","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"ONEDATA","dateModified":"2012-04-25","deletedIndicator":"No"},{"value":"pT1","valueDescription":"Tumor present, but not detectable clinically or with imaging","ValueMeaning":{"publicId":"3442956","version":"1","preferredName":"Tumor present, but not detectable clinically or with imaging","longName":"3442956","preferredDefinition":"A pathologic primary tumor TNM stage finding.  The definition of pT1 stage finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1 stage finding is defined as follows: cancer with tumor size 2.0 cm or less in greatest dimension; for colorectal cancer, pT1 stage finding is defined as follows: cancer with invasion into the submucosa. (from AJCC 6th and 7th Eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"pT1 TNM Finding","conceptCode":"C48759","definition":"A pathologic primary tumor TNM finding.  The definition of pT1 finding depends on the particular type of cancer that it refers to; for example, for breast cancer, pT1 finding is defined as follows: cancer with tumor size 2.0 cm or less in greatest dimension; for colorectal cancer, pT1 stage finding is defined as follows: cancer with invasion into the submucosa. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE8A053C-B4F6-0643-E040-BB89AD436B32","latestVersionIndicator":"Yes","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BE8A053C-B50F-0643-E040-BB89AD436B32","beginDate":"2012-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-25","modifiedBy":"ONEDATA","dateModified":"2012-04-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3135388","version":"1","preferredName":"Prostate Carcinoma Pathologic T Stage Stage","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:Pathologic; caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C4863:C25610:C25728:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-6543-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC04DC3-6554-CF3E-E040-BB89AD43512D","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"COOPERM","dateModified":"2012-04-25","changeDescription":"Added 4 PVs for T1 stage findings per request by T.Lichtenberg. mc 4/25/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787499","version":"1","longName":"BLCA","context":"NCIP"}]}],"AlternateNames":[{"name":"person_concomitant_prostate_carcinoma_pathologic_t_stage","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"Pathologic Spread for Inciden","type":"Preferred Question Text","description":"Pathologic Spread for Incidental Prostate Cancer","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC2B62E-8C06-FC2A-E040-BB89AD435F5A","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"TSESU","dateModified":"2018-07-12","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) by request of T. Lichtenberg 9/2010","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}